Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions

Sondos Zayed, Alexander V Louie, Daniel A Breadner, David A Palma, Rohann J M Correa, Sondos Zayed, Alexander V Louie, Daniel A Breadner, David A Palma, Rohann J M Correa

Abstract

The combined use of stereotactic ablative radiotherapy (SABR) and immune checkpoint inhibitors (ICIs) is an emerging treatment paradigm for oligometastatic non-small-cell lung cancer (NSCLC). Recent phase I and II trial data suggest that SABR to multiple metastases in addition to ICI use is safe and effective with promising progression-free survival and overall survival signals. There is great interest in capitalizing on combined immunomodulation from these two modalities for the treatment of oligometastatic NSCLC. Ongoing trials seek to validate the safety, efficacy, and preferred sequencing of SABR and ICI. This narrative review of the role of SABR when combined with ICI in oligometastatic NSCLC discusses the rationale for this bimodality treatment, summarizes recent clinical trial evidence, and proposes key principles of management based on the available evidence.

Keywords: immune checkpoint inhibitors; immunotherapy; non-small-cell lung cancer; oligometastasis; stereotactic ablative radiotherapy.

Conflict of interest statement

Dr. Louie has received honoraria from AstraZeneca, unrelated to this review. Dr. Breadner has honoraria from Astra Zeneca, Bristol Myers Squibb, Takeda, Merck, and Amgen, unrelated to this review.

© The Author(s), 2023.

Figures

Figure 1.
Figure 1.
Synchronous oligometastatic disease. A patient with oligometastatic lung cancer at diagnosis with three metastases receives systemic therapy as well as SABR to all gross sites of disease. SABR, stereotactic ablative radiotherapy.
Figure 2.
Figure 2.
Metachronous oligometastatic disease. A patient with localized lung cancer at diagnosis received local treatment and eventually develops OMD with three new metastatic deposits. The patient then receives systemic therapy as well as SABR to all gross sites of disease. *Note that although some patients will receive systemic therapy for metachronous OMD in addition to SABR, others will receive local therapies only (e.g. SABR and/or surgery). OMD, oligometastatic disease; SABR, stereotactic ablative radiotherapy.
Figure 3.
Figure 3.
Proposed management principles for treatment of oligometastatic disease with SABR and ICIs. (1) Careful patient selection; (2) caution with concurrent SABR and ICI; (3) ablate all sites of disease; and (4) minimize toxicity. ICI, immune checkpoint inhibitor; OAR, organ at risk; RT, radiation therapy; SABR, stereotactic ablative radiotherapy.

References

    1. Ashworth A, Rodrigues G, Boldt G, et al.. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer 2013; 82: 197–203.
    1. Lievens Y, Guckenberger M, Gomez D, et al.. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol 2020; 148: 157–166.
    1. Palma DA, Salama JK, Lo SS, et al.. The oligometastatic state – separating truth from wishful thinking. Nat Rev Clin Oncol 2014; 11: 549–557.
    1. Iyengar P, Wardak Z, Gerber DE, et al.. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 2018; 4: e173501.
    1. Gomez DR, Blumenschein GR, Jr, Lee JJ, et al.. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016; 17: 1672–1682.
    1. Gomez DR, Tang C, Zhang J, et al.. Local consolidative therapy vs. Maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol 2019; 37: 1558–1565.
    1. Antonia SJ, Villegas A, Daniel D, et al.. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377: 1919–1929.
    1. Gadgeel S, Rodriguez-Abreu D, Speranza G, et al.. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 2020; 38: 1505–1517.
    1. Paz-Ares L, Vicente D, Tafreshi A, et al.. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J Thorac Oncol 2020; 15: 1657–1669.
    1. Powell SF, Rodriguez-Abreu D, Langer CJ, et al.. Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407. J Thorac Oncol 2021; 16: 1883–1892.
    1. Reck M, Rodriguez-Abreu D, Robinson AG, et al.. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol 2019; 37: 537–546.
    1. Green BN, Johnson CD, Adams A.Writing narrative literature reviews for peer-reviewed journals: secrets of the trade. J Chiropr Med 2006; 5: 101–117.
    1. Hellman S, Weichselbaum RR.Oligometastases. J Clin Oncol 1995; 13: 8–10.
    1. Weichselbaum RR, Hellman S.Oligometastases revisited. Nat Rev Clin Oncol 2011; 8: 378–382.
    1. Palma DA, Olson R, Harrow S, et al.. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019; 393: 2051–2058.
    1. Chapman ER, Correa RJM, Palma DA, et al.. Stereotactic ablative radiotherapy for oligometastatic disease: a tale of emperor’s new clothes or new standard of care? Clin Oncol (R Coll Radiol) 2022; 34: 318–324.
    1. Zayed S, Correa RJM, Palma DA.Radiation in the treatment of oligometastatic and oligoprogressive disease: rationale, recent data, and research questions. Cancer J 2020; 26: 156–165.
    1. Olson R, Senan S, Harrow S, et al.. Quality of life outcomes after stereotactic ablative radiotherapy (SABR) versus standard of care treatments in the oligometastatic setting: a secondary analysis of the SABR-COMET randomized trial. Int J Radiat Oncol Biol Phys 2019; 105: 943–947.
    1. Vilela RA, Navarro NF, Faria ET, et al.. Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: a systematic review. J Med Imaging Radiat Oncol 2018; 62: 692–706.
    1. Wintner LM, Giesinger JM, Zabernigg A, et al.. Quality of life during chemotherapy in lung cancer patients: results across different treatment lines. Br J Cancer 2013; 109: 2301–2308.
    1. Qu MX, Chen Y, Zaric G, et al.. Is SABR cost-effective in oligometastatic cancer? an economic analysis of SABR-Comet. Int J Radiat Oncol Biol Phys 2021; 109: 1176–1184.
    1. Tjong MC, Louie AV, Iyengar P, et al.. Local ablative therapies in oligometastatic NSCLC-upfront or outback?-a narrative review. Transl Lung Cancer Res 2021; 10: 3446–3456.
    1. Harrow S, Palma DA, Olson R, et al.. Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET) - extended long-term outcomes. Int J Radiat Oncol Biol Phys 2022; 114: 611–616.
    1. Turchan WT, Chmura SJ.The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review. Ann Palliat Med 2021; 10: 6028–6044.
    1. Baker S, Jiang W, Mou B, et al.. Progression-free survival and local control following stereotactic ablative radiotherapy for up to 5 oligometastases: an analysis from the population-based phase II SABR-5 trial. Int J Radiat Oncol Biol Phys 2022; 114: 617–626.
    1. Reck M, Rodriguez-Abreu D, Robinson AG, et al.. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823–1833.
    1. Bagchi S, Yuan R, Engleman EG.Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol 2021; 16: 223–249.
    1. Goldberg MV, Drake CG.LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol 2011; 344: 269–278.
    1. Niu J, Maurice-Dror C, Lee DH, et al.. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer (☆). Ann Oncol 2022; 33: 169–180.
    1. Aggarwal C, Prawira A, Antonia S, et al.. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. J Immunother Cancer 2022; 10: e004424.
    1. Spigel DR, Faivre-Finn C, Gray JE, et al.. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 2022; 40: 1301–1311.
    1. Nosaki K, Saka H, Hosomi Y, et al.. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer 2019; 135: 188–195.
    1. Paz-Ares LG, Ciuleanu T-E, Cobo-Dols M, et al.. First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA. J Clin Oncol 2022; 40: LBA9026–LBA9026.
    1. Paz-Ares LG, Ramalingam SS, Ciuleanu TE, et al.. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J Thorac Oncol 2022; 17: 289–308.
    1. Gutiontov SI, Pitroda SP, Chmura SJ, et al.. Cytoreduction and the Optimization of immune checkpoint inhibition with radiation therapy. Int J Radiat Oncol Biol Phys 2020; 108: 17–26.
    1. Hou PF, Zhu LJ, Pan Y, et al.. The relationship between regulatory T cells and radiation therapy. Cancer Radiother 2020; 24: 81–84.
    1. Liu C, Sun B, Hu X, et al.. Stereotactic ablative radiation therapy for pulmonary recurrence-based oligometastatic non-small cell lung cancer: survival and prognostic value of regulatory T cells. Int J Radiat Oncol Biol Phys 2019; 105: 1055–1064.
    1. Buchbinder EI, Desai A.CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 2016; 39: 98–106.
    1. Muroyama Y, Nirschl TR, Kochel CM, et al.. Stereotactic radiotherapy increases functionally suppressive regulatory T cells in the tumor microenvironment. Cancer Immunol Res 2017; 5: 992–1004.
    1. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al.. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014; 74(19):5458–5468.
    1. Miyamoto S, Nomura R, Sato K, et al.. Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer. Jpn J Clin Oncol 2019; 49: 160–164.
    1. Mattes MD, Eubank TD, Almubarak M, et al.. A prospective trial evaluating the safety and systemic response from the concurrent use of radiation therapy with checkpoint inhibitor immunotherapy in metastatic non-small cell lung cancer. Clin Lung Cancer 2021; 22: 268–273.
    1. Ye H, Pang H, Shi X, et al.. Nivolumab and hypofractionated radiotherapy in patients with advanced lung cancer: ABSCOPAL-1 clinical trial. Front Oncol 2021; 11: 657024.
    1. Theelen W, Peulen HMU, Lalezari F, et al.. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol 2019; 5: 1276–1282.
    1. Bestvina CM, Pointer KB, Karrison T, et al.. A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC study. J Thorac Oncol 2022; 17: 130–140.
    1. Bauml JM, Mick R, Ciunci C, et al.. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial. JAMA Oncol 2019; 5: 1283–1290.
    1. Chen Y, Wang Y, Yang Z, et al.. Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: a retrospective observational study. Thorac Cancer 2022; 13: 732–741.
    1. Miyawaki T, Kenmotsu H, Harada H, et al.. Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L). BMC Cancer 2021; 21: 1121.
    1. Palma DA, Olson R, Harrow S, et al.. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 2020; 38: 2830–2838.
    1. Jasper K, Stiles B, McDonald F, et al.. Practical management of oligometastatic non-small-cell lung cancer. J Clin Oncol 2022; 40: 635–641.
    1. Shaverdian N, Lisberg AE, Bornazyan K, et al.. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017; 18: 895–903.
    1. Anscher MS, Arora S, Weinstock C, et al.. Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US food and drug administration database. JAMA Oncol 2022; 8: 232–240.
    1. Centanni M, Moes D, Troconiz IF, et al.. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet 2019; 58: 835–857.
    1. Spaas MSNora; Rottey, Sylvie; Kruse, et al.. Immuno-radiotherapy in solid tumors: preliminary results of the randomized phase 2 CHEERS trial. Radiother Oncol 2021; 161: 490–491.
    1. Kroeze SGC, Pavic M, Stellamans K, et al.. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol 2023; 24: e121–e132.
    1. Hatten SJ, Jr., Lehrer EJ, Liao J, et al.. A patient-level data meta-analysis of the abscopal effect. Adv Radiat Oncol 2022; 7: 100909.
    1. Theelen W, Chen D, Verma V, et al.. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 2021; 9: 467–475.
    1. Welsh J, Menon H, Chen D, et al.. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer 2020; 8: e001001.
    1. Palma DA, Olson R, Harrow S, et al.. Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer 2019; 19: 816.
    1. Khunger M, Rakshit S, Pasupuleti V, et al.. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 2017; 152: 271–281.
    1. Shibaki R, Akamatsu H, Fujimoto M, et al.. Nivolumab induced radiation recall pneumonitis after two years of radiotherapy. Ann Oncol 2017; 28: 1404–1405.
    1. Korpics MC, Katipally RR, Partouche J, et al.. Predictors of pneumonitis in combined thoracic stereotactic body radiotherapy and immunotherapy. Int J Radiat Oncol Biol Phys 2022; 114: 645–654.
    1. Palma DA, Olson R, Harrow S, et al.. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer 2019; 19: 816.
    1. Gerhard SG, Palma DA, Arifin AJ, et al.. Organ at risk dose constraints in SABR: a systematic review of active clinical trials. Pract Radiat Oncol 2021; 11: e355–e365.
    1. Diez P, Hanna GG, Aitken KL, et al.. UK 2022 consensus on normal tissue dose-volume constraints for oligometastatic, primary lung and hepatocellular carcinoma stereotactic ablative radiotherapy. Clin Oncol (R Coll Radiol) 2022; 34: 288–300.
    1. Grimm J, Marks LB, Jackson A, et al.. High dose per fraction, hypofractionated treatment effects in the clinic (HyTEC): an overview. Int J Radiat Oncol Biol Phys 2021; 110: 1–10.
    1. Ueki N, Matsuo Y, Togashi Y, et al.. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer. J Thorac Oncol 2015; 10: 116–125.
    1. van der Kooij MK, Suijkerbuijk KPM, Aarts MJB, et al.. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease: a cohort study. Ann Intern Med 2021; 174: 641–648.
    1. Brozos-Vazquez EM, Diaz-Pena R, Garcia-Gonzalez J, et al.. Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy. Cancer Immunol Immunother 2021; 70: 1177–1188.
    1. Hegi-Johnson F, Rudd S, Hicks RJ, et al.. Imaging immunity in patients with cancer using positron emission tomography. NPJ Precis Oncol 2022; 6: 24.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner